Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease
Yükleniyor...
Dosyalar
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Iranian Soc Nephrolgy
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Fabry disease, an X-linked lysosomal storage disorder, is caused by alpha-galactosidase A deficiency and leads to accumulation of glycospinhgolipids in most tissues, with life-theratening consequences in the kidney, heart, and cerebrovascular system. Enzyme replacement therapy is available as 2 different preparations: agalsidase alfa and agalsidase beta. Enzyme replacement therapy is started as soon as the diagnosis is confirmed, but there is no data available in the literature about its safety during preganacy. Herein, we described 2 patients with Fabry disease who received agalsidase beta during their pregnancy. This report is important as the data about enzyme replacement therapy during pregnancy is restricted with case reports.
Açıklama
WOS: 000363832600010
PubMed: 26338166
PubMed: 26338166
Anahtar Kelimeler
Fabry disease, pregnancy, agalsidase beta, enzyme replacement
Kaynak
Iranian Journal Of Kidney Diseases
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
9
Sayı
5
